7,8,8] naphthyridine-3-carboxylate (ITH4012) is a novel tacrine derivative that can reduce cell death induced by various compounds with different mechanisms of action, such as thapsigargin (reticular stress), H 2 O 2 (free radicals), and veratridine (calcium overload), in bovine chromaffin cell. Cell viability, quantified as lactic dehydrogenase release, was significantly reduced by ITH4012 at concentrations ranging from 0.01 to 3 M. In the human neuroblastoma cell line SH-SY5Y, ITH4012 also reduced amyloid  25-35 -induced apoptosis, determined by flow cytometry. ITH4012 caused a slight elevation in the cytosolic concentration of Ca 2ϩ in fura 2-loaded bovine chromaffin cells, which could be related to the induction of protein synthesis relevant for cell survival. Blockade of protein synthesis by cycloheximide or blockade of Bcl-2's active site with HA14-1 (ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate) reversed the cytoprotective action of ITH4012. Furthermore, exposure of bovine chromaffin cells for 24 or 48 h to neuroprotective concentrations of this compound enhanced, nearly 3-fold, the expression of the antiapoptotic protein Bcl-2. In conclusion, ITH4012 is a tacrine derivative that maintains acetylcholinesterase-inhibiting activity (IC 50 ϭ 0.8 M) but has the additional property of acting as a calcium promotor, a property leading to neuroprotection through the induction of antiapoptotic proteins.Alzheimer's disease (AD) is a degenerative disorder of the central nervous system found primarily among the aged. It is the most common type of dementia in western societies and has been creating profound economic and social impacts as the elderly population continues to increase (Guttman et al., 1999). The hallmarks of the illness are extracellular deposition of neuritic plaques of amyloid- peptide (A), intracellular formation of neurofibrillary tangles, and selective neuronal loss. Of all biochemical changes observed in AD patients, only the reduction in number of functional neuronal nicotinic receptors is related to neuropsychiatric symptoms (Schroder et al., 1991). For this reason, the only pharmacotherapeutical strategy that, until now, has proven to have some efficacy in slowing progression of the illness is that which improves cholinergic neurotransmission, counteracting the deficit of cerebral acetylcholine (Standaert and Young, 1996). Therefore, acetylcholinesterase inhibition is currently the therapeutic strategy most commonly used to treat Alzheimer's patients.On the other hand, moderate chronic depolarization has demonstrated an ability to increase the survival of different neuronal types. Also, there is evidence that this effect is mediated by the mild and sustained elevation of [Ca 2ϩ ] c ,